AUPH
Aurinia Pharmaceuticals Inc. NASDAQ Listed Sep 3, 2014$15.14
Mkt Cap $2.0B
52w Low $7.29
81.9% of range
52w High $16.88
50d MA $15.13
200d MA $13.89
P/E (TTM)
7.2x
EV/EBITDA
16.7x
P/B
3.5x
Debt/Equity
0.1x
ROE
36.3%
P/FCF
15.8x
RSI (14)
—
ATR (14)
—
Beta
1.52
50d MA
$15.13
200d MA
$13.89
Avg Volume
1.1M
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
4464 Markham Street · Edmonton, BC V8Z 7X8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.21 | 0.26 | +23.8% | 13.97 | +0.1% | +1.4% | +1.7% | +1.3% | +7.7% | +5.5% | — |
| Nov 4, 2025 | AMC | 0.16 | 0.23 | +43.8% | 14.27 | -3.4% | +1.3% | -2.2% | +2.4% | +4.3% | +9.9% | — |
| Jul 31, 2025 | AMC | 0.17 | 0.16 | -5.9% | 9.24 | +1.3% | +13.5% | +23.9% | +26.6% | +25.6% | +23.7% | — |
| May 12, 2025 | AMC | 0.08 | 0.16 | +100.0% | 8.12 | +0.7% | -3.7% | -3.3% | +0.4% | +0.9% | -0.6% | — |
| Feb 27, 2025 | AMC | 0.03 | 0.09 | +200.0% | 7.55 | -1.1% | +5.3% | +5.7% | +7.0% | +14.8% | +8.5% | — |
| Nov 7, 2024 | AMC | 0.01 | 0.10 | +566.7% | 8.34 | +0.6% | -0.2% | +1.8% | +0.5% | -0.7% | -0.1% | — |
| Aug 1, 2024 | AMC | 0.02 | 0.02 | +19.8% | 5.61 | -2.0% | -2.0% | -4.3% | +0.2% | -5.2% | -2.5% | — |
| May 2, 2024 | AMC | -0.17 | -0.03 | +82.4% | 5.17 | +4.4% | -1.4% | -0.2% | -1.0% | -0.4% | +0.0% | — |
| Apr 16, 2024 | AMC | -0.14 | -0.07 | +50.0% | 5.00 | +0.8% | -1.8% | -3.8% | -0.2% | +1.0% | +1.8% | — |
| Nov 2, 2023 | AMC | -0.17 | -0.09 | +47.1% | 7.88 | +0.5% | +4.4% | +5.2% | +5.2% | +2.3% | -3.8% | — |
| Aug 3, 2023 | AMC | -0.18 | -0.08 | +55.6% | 10.56 | +0.3% | -7.0% | -7.7% | -8.0% | -10.4% | -9.5% | — |
| May 4, 2023 | AMC | -0.22 | -0.18 | +18.2% | 11.34 | +1.6% | +1.9% | -1.3% | -1.2% | -0.9% | -3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $15.91 | $15.61 | -1.9% | -6.3% | -3.8% | -1.8% | -1.4% | -2.4% |
| Nov 7 | Jefferies | Upgrade | Hold → Buy | — | $13.95 | $14.60 | +4.7% | +4.7% | +6.7% | +12.4% | +11.4% | +9.1% |
| Nov 5 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $14.27 | $13.78 | -3.4% | +1.3% | -2.2% | +2.4% | +4.3% | +9.9% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $9.24 | $9.36 | +1.3% | +13.5% | +23.9% | +26.6% | +25.6% | +23.7% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.03 | $7.10 | +1.0% | +1.4% | +1.6% | +0.7% | +2.4% | +2.4% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.26 | $7.25 | -0.1% | -5.4% | -9.6% | -10.1% | -9.4% | -3.2% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $6.93 | +0.3% | +5.1% | -0.6% | -5.1% | -5.5% | -4.8% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.72 | $5.73 | +0.2% | +1.0% | +0.7% | -2.1% | -3.5% | -4.7% |
| Feb 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.00 | $5.96 | -0.7% | -0.8% | +0.0% | +0.3% | -2.7% | -4.7% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.70 | -0.7% | +4.5% | +3.7% | +4.5% | +4.9% | +1.7% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $6.02 | $5.92 | -1.7% | -2.8% | -7.1% | -4.7% | -0.3% | -1.2% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.34 | +0.8% | +1.0% | -1.9% | -1.2% | -3.5% | -4.7% |
| Aug 7 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $9.82 | $9.81 | -0.1% | -0.7% | -1.1% | -3.7% | -2.6% | -3.3% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.95 | $9.76 | -1.9% | +1.7% | +3.4% | +7.8% | +14.6% | +11.6% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $11.65 | +0.6% | +0.9% | -2.1% | -0.2% | -3.4% | -3.3% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $7.91 | $8.00 | +1.1% | +6.2% | +3.5% | +5.3% | +14.9% | +13.7% |
| Jan 4 | RBC Capital | Maintains | Outperform → Outperform | — | $5.94 | $6.05 | +1.9% | +13.1% | +16.0% | +27.1% | +26.8% | +30.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.17 | +0.4% | -1.9% | +4.5% | -2.3% | +3.3% | +2.7% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $5.18 | $5.25 | +1.4% | -0.6% | -2.5% | +3.9% | -2.9% | +2.7% |
| Nov 4 | Oppenheimer | Downgrade | Outperform → Perform | — | $5.18 | $5.25 | +1.4% | -0.6% | -2.5% | +3.9% | -2.9% | +2.7% |
| Nov 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.18 | $5.25 | +1.4% | -0.6% | -2.5% | +3.9% | -2.9% | +2.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.08 | -2.3% | -1.7% | +2.8% | -1.2% | +1.8% | +4.4% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.37 | $8.30 | -0.8% | -1.2% | -2.9% | +1.6% | -2.4% | +0.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.37 | $11.29 | -0.7% | -4.6% | -10.6% | -21.3% | -0.9% | -15.7% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $10.80 | $10.78 | -0.2% | -2.6% | -4.7% | +0.8% | +3.0% | +5.3% |
| Mar 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $10.67 | $10.54 | -1.2% | -5.2% | +6.7% | +1.4% | -0.5% | -5.8% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $12.30 | $12.30 | +0.0% | -2.4% | -5.5% | -11.5% | -14.0% | -13.3% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $15.80 | $16.17 | +2.3% | -2.9% | +1.1% | +2.8% | -22.2% | -24.0% |
| Dec 10 | Oppenheimer | Upgrade | Perform → Outperform | — | $20.97 | $21.57 | +2.9% | -4.0% | -5.1% | -14.1% | -5.2% | -6.2% |
| Nov 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $30.39 | $30.98 | +1.9% | +5.0% | +5.2% | +3.1% | -1.1% | -2.5% |
| Nov 4 | Oppenheimer | Maintains | Perform → Perform | — | $30.39 | $30.98 | +1.9% | +5.0% | +5.2% | +3.1% | -1.1% | -2.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.39 | $30.98 | +1.9% | +5.0% | +5.2% | +3.1% | -1.1% | -2.5% |
| Oct 28 | Oppenheimer | Downgrade | Outperform → Perform | — | $29.92 | $28.98 | -3.1% | +0.1% | +10.6% | +9.1% | +7.0% | +1.6% |
| Oct 26 | RBC Capital | Maintains | Outperform → Outperform | — | $29.84 | $29.80 | -0.1% | +1.7% | +0.3% | +0.4% | +10.9% | +9.3% |
| Jan 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.62 | $16.77 | -4.8% | -8.9% | -3.1% | -5.2% | -7.7% | -8.9% |
| Jan 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.86 | $20.50 | +38.0% | +26.0% | +18.6% | +8.0% | +14.9% | +12.4% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.50 | $13.87 | -10.5% | -9.9% | -10.6% | -8.1% | -11.2% | -10.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.00 | $13.76 | -1.7% | +1.3% | +1.2% | +0.1% | +3.6% | +2.9% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.48 | $15.39 | +6.3% | +15.1% | -3.7% | -3.9% | -4.8% | -7.2% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.81 | $18.27 | -2.9% | -10.4% | -17.8% | -18.2% | -25.0% | -31.8% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.50 | +0.1% | +0.2% | +7.3% | +4.0% | +5.5% | +6.5% |
| Dec 16 | H.C. Wainwright | Maintains | Buy → Buy | — | $18.48 | $18.50 | +0.1% | +0.2% | +7.3% | +4.0% | +5.5% | +6.5% |
| Sep 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.80 | $6.00 | +3.4% | +12.8% | +12.2% | +11.2% | +13.6% | +10.5% |
| Mar 20 | Raymond James | Maintains | Outperform → Outperform | — | $6.42 | $6.80 | +5.9% | +6.4% | +5.1% | +0.8% | +2.6% | +2.8% |
| Feb 8 | RBC Capital | Maintains | Outperform → Outperform | — | $5.17 | $5.40 | +4.4% | -2.1% | -1.4% | +0.8% | +1.5% | +2.9% |
| Oct 23 | Leerink Swann | Maintains | Outperform → Outperform | — | $6.15 | $6.21 | +1.0% | -1.8% | -6.5% | -5.4% | -8.8% | -7.2% |
| Oct 6 | Seaport Global | Maintains | Buy → Buy | — | $6.50 | $6.61 | +1.7% | +0.9% | -1.2% | -1.1% | -0.2% | +1.2% |
| Sep 13 | Canaccord Genuity | Maintains | Buy → Speculative Buy | — | $6.38 | $6.30 | -1.3% | -2.8% | -0.9% | -1.7% | -1.7% | -2.7% |
| Apr 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.05 | $7.00 | -0.7% | -0.7% | +0.7% | -1.6% | -3.1% | -5.1% |
No insider trades available.
8-K · 2.02
!! High
Aurinia Pharmaceuticals Inc. -- 8-K 2.02: Earnings Results
Aurinia Pharmaceuticals reported Q1 2026 financial results, providing investors visibility into the company's operational performance and financial condition for the quarter ended March 31, 2026.
May 7
SC TO-T
!!! Very High
Unknown — Tender Offer
A tender offer for AUPH and KZR suggests potential acquisition or restructuring, making these stocks volatile short-term plays where investors should evaluate the offer price versus current trading levels and regulatory approval odds.
Apr 13
8-K
Unknown — 8-K Filing
The merger agreement requires all unvested restricted stock units to vest immediately before closing, potentially diluting shareholders and increasing acquisition costs for the acquirer.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Three executives departing simultaneously signals organizational instability and increases near-term execution risk for both AUPH and KZR, likely pressuring stock prices until replacement leadership is announced.
Apr 3
8-K
Unknown — 8-K Filing
Contingent value rights (CVRs) offering shareholders potential future cash payments beyond the current offer price, which could indicate undervaluation concerns or incomplete deal certainty warranting investor caution.
Mar 30
8-K
Unknown — 8-K Filing
Aurinia's executive leadership transition with a new COO appointment signals operational restructuring; the CEO's voluntary compensation waiver suggests confidence in turnaround strategy, potentially reducing near-term cash burn.
Mar 23
8-K
Aurinia Pharmaceuticals Inc -- 8-K Filing
Aurinia Pharmaceuticals reported full-year and fourth-quarter 2025 financial results, disclosing operational performance through year-end that investors can use to assess revenue trends and cash position.
Feb 26
Data updated apr 24, 2026 7:49pm
· Source: massive.com